Clinical Development

Brought to you by:
failure crash no fail rocket cancelled end
Biotech

Alto's midphase depression trial falls flat

A phase 2b trial of Alto’s lead drug candidate in depression missed its primary and key secondary endpoints, wiping 60% off the biotech’s share price.
Nick Paul Taylor Oct 23, 2024 4:47am
eye eyeball eye art

China-based biotech plans ph. 3 after seeing midstage eye data

Oct 22, 2024 10:37am
Hybrid FSPFSO Solutions Keep Biotech Trials on Time and on Budget

Hybrid FSP/FSO Solutions Keep Biotech Trials on Time and on Budget

Nov 1, 2024 8:00am
HIV AIDS PREP

Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks

Oct 21, 2024 5:06am
Market Insights Whats Driving the Shift Toward FSP Models in Clinical Development

Market Insights: What’s Driving the Shift Toward FSP Models in Clinical Development?

Oct 2, 2024 8:00am
Man on chair with head in hand

Supernus links depression drug to fast responses in ph. 2 trial

Oct 18, 2024 9:17am